Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 249

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

Open access
Du, Xuexiang, Tang, Fei, Liu, Mingyue, Su, Juanjuan, Zhang, Yan, Wu, Wei, Devenport, Martin, Lazarski, Christopher A, Zhang, Peng, Wang, Xu, Ye, Peiying, Wang, Changyu, Hwang, Eugene, Zhu, Tinghui, Xu, Ting, Zheng, Pan, Liu, Yang·2018·Cell Research

Abstract

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blocking negative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrations considerably higher than plasma levels achieved by clinically effective dosing, the anti-CTLA-4 antibody Ipilimumab blocks neither B7 trans-endocytosis by CTLA-4 nor CTLA-4 binding to immobilized or cell-associated B7. Consequently, Ipilimumab does not increase B7 on dendritic cells (DCs) from either CTLA4 gene humanized ( Ctla4 h/h ) or human CD34 + stem cell-reconstituted NSG™ mice. In Ctla4 h/m mice expressing both human and mouse CTLA4 genes, anti-CTLA-4 antibodies that bind to human but not mouse CTLA-4 efficiently induce Treg depletion and Fc receptor-dependent tumor rejection. The blocking antibody L3D10 is comparable to the non-blocking Ipilimumab in causing tumor rejection. Remarkably, L3D10 progenies that lose blocking activity during humanization remain fully competent in inducing Treg depletion and tumor rejection. Anti-B7 antibodies that effectively block CD4 T cell activation and de novo CD8 T cell priming in lymphoid organs do not negatively affect the immunotherapeutic effect of Ipilimumab. Thus, clinically effective anti-CTLA-4 mAb causes tumor rejection by mechanisms that are independent of checkpoint blockade but dependent on the host Fc receptor. Our data call for a reappraisal of the CTLA-4 checkpoint blockade hypothesis and provide new insights for the next generation of safe and effective anti-CTLA-4 mAbs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41422-018-0011-0

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 249

Metadata

Authors
Du, X., Tang, F., Liu, M., Su, J., Zhang, Y., Wu, W., Devenport, M., Lazarski, C. A., Zhang, P., Wang, X., Ye, P., Wang, C., Hwang, E., Zhu, T., Xu, T., Zheng, P., & Liu, Y.
Venue
Cell Research
Published
2018-02-22
Volume
28
Issue
4
Pages
416-432
ISSN
  • 1001-0602 (ISSN-L)
  • 1748-7838
OpenAlex
W2790795290
Cited by
249
References
10
FWCI
10.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41422-018-0011-0
The paper
Du, X., Tang, F., Liu, M., Su, J., Zhang, Y., Wu, W., Devenport, M., Lazarski, C. A., Zhang, P., Wang, X., Ye, P., Wang, C., Hwang, E., Zhu, T., Xu, T., Zheng, P., & Liu, Y. (2018). A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Research. https://doi.org/10.1038/s41422-018-0011-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.